This article is more than 5 years old. Information may no longer be current.

Ophthalmology academy highlights AMD, genomics, glaucoma, refractive surgery

Issue: December 2005

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO – Here at the American Academy of Ophthalmology meeting, researchers reported on potential age-related macular degeneration treatments. According to Philip J. Rosenfeld, MD, PhD, the VEGF-blocking agent bevacizumab is attractively priced for this off-label ophthalmic application, but its safety profile in the eye is unknown.

Robert N. Weinreb, MD, described a handheld calculator for predicting glaucoma progression risk in those with hypertension.

Genomics pioneer Francis S. Collins, MD, said that ophthalmology is on the cutting edge of genomics, a field of study that will enable practitioners to make diagnostic predictions about who is at risk for a disease.

Scott M. MacRae, MD, referred to LASIK and corneal surface ablation approaches as “complementary procedures,” each with their own set of advantages and disadvantages.

For more on the American Academy of Ophthalmology meeting, click on the article links below:

• New glaucoma risk assessment tool helps identify patients in need of treatment
• Surface ablation, LASIK each have clinical advantages
• Systemic AMD treatment shows promise, must be studied prospectively
• Genomics pioneer says ophthalmology is ahead of the genetic pack